Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. - Test2 - elhamkhani - TriplyDB

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.

http://www.wikidata.org/entity/Q36782688

about

Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Cardiovascular safety of anti-diabetic drugs The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review Insulin resistance and skeletal muscle vasculature: significance, assessment and therapeutic modulators Management standards for stable coronary artery disease in India.Management Protocols of stable coronary artery disease in India: Executive summary.Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study.Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Cardiovascular safety profile of currently available diabetic drugs.Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span.Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke Metformin and Myocardial Injury in Patients With Diabetes and ST-Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis.Longitudinal Patterns of Blood Pressure, Incident Cardiovascular Events, and All-Cause Mortality in Normotensive Diabetic People New insights into insulin action and resistance in the vasculature.Type 2 diabetes and cardiovascular disease: what next?Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.Translating the Science of Aging into Therapeutic Interventions.Metformin: A Hopeful Promise in Aging Research.Cardiovascular effects of anti-diabetes drugs.Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.Long-term studies of treatments for type 2 diabetes.The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.A review on cardiovascular effects of newer hypoglycaemic medications.Effects of glucose-lowering agents on ischemic stroke.The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction.Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.

P2860

Q22241119-2454A2A3-A05C-4E9A-8CA0-5D41B63AB2E7 Q26740253-43307C7E-BFA2-4844-8268-ACAF282F721F Q26741082-B47D5AFC-2F30-4B10-B280-FF04473981E5 Q26748870-A6652ACD-5447-458B-B7AB-6807EA83533D Q26749281-5503E621-FCCF-44F0-8D0B-E36E9B5E4735 Q27687851-53C3D2C2-55C4-428A-8D42-FBB5DCAC4011 Q28071386-C57ABA75-399A-4533-8D6D-5DB5B1238455 Q28081458-6C85F9F1-EB04-42C3-8ED8-A78721D59656 Q30239853-C29DF804-D0AC-4E1C-A22D-014287F13A5D Q30240155-857F733B-2B8D-427A-A0D4-545E49E778E6 Q33618721-AC76A0BB-B253-4639-968D-67B4CC77BE38 Q33705903-A5D86DBE-C0A7-4816-B7E3-44002D59BE5E Q33708461-61B0E3A6-8039-48EB-AB9F-5FA26E7D875A Q33727891-C0354819-5E0E-449F-B8AB-7408294091B5 Q33815573-E3119CB1-3CD3-4BFC-B9AD-58054195C397 Q34971736-A94B954C-0F41-4BED-93BC-0DD8D0101A1C Q35044151-E2E785D7-7B9C-4DB8-A97C-4517D5043804 Q35961020-DBF7206F-0FD4-4921-8D73-CEACC1F9BE7A Q36406255-944E4863-9285-4817-8B81-3B32BE467529 Q36520595-F419F2A0-BD57-4001-95C8-FBA5A0203C3A Q36836016-B90F7BF6-A42A-4123-ABF0-2D032D558AB0 Q37170469-36F81644-2DC9-478B-A005-5E41BFDA40CE Q37707789-6F970057-54FC-47C8-A548-48C2226D5756 Q38191133-91DC6C82-7139-41D8-B92A-B9AE298DFA89 Q38364806-0E7433EE-0386-4166-BC1F-EBA3638BB676 Q38377128-DEECCF03-806F-4710-ACAA-6A64AFA98B50 Q38524435-CBF1BBED-C238-4BE2-8068-89736DE48B6B Q38644587-1DBF6591-6C4D-401C-B301-2170B47B1D78 Q38737909-1995B7A7-BA42-4F45-BC77-7804B2F3FC35 Q38756902-4DF0BE0F-EEC9-4FD3-9261-877355175F8D Q38756907-183DC9E7-892B-4011-B9BC-BF50EF6F4553 Q38857056-13BDD555-4143-437E-8F2F-71C8F9CE542B Q39000136-D7465493-C3B9-4AB0-91A7-9553C46C8812 Q39018646-74999F4E-0948-41FC-A8E9-E6E278A9DD70 Q39123582-D1858E0C-0223-4D7C-9B06-9533BA4E78FD Q39136054-7EDE3A31-DCE5-46F0-8AE6-A022120F63D5 Q39328296-9DDC1323-3B76-4E53-9D21-BA88BC2177A0 Q39427199-A6AF57F1-454E-481E-A18F-2ACC91016C6B Q40842440-F521D20B-78B0-4273-9F65-E0323B2FDAF1 Q40844288-BE1501E8-AC2B-4B6A-87C0-D4F237F39CBC

P2860

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.

http://www.wikidata.org/entity/Q36782688

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Effects of metformin versus gl ...... s and coronary artery disease.

@en

type

label

Effects of metformin versus gl ...... s and coronary artery disease.

@en

prefLabel

Effects of metformin versus gl ...... s and coronary artery disease.

@en

P1433

Q36782688-C1550247-DA87-4845-BF84-4403010FED10

P1476

Q36782688-144EA2BA-A6CC-4E27-A02D-A017CA41E00C

P2093

Q36782688-07CEF129-72E0-42AF-A947-F6BADA1F7942

Q36782688-11AD3C7C-0FF6-4EA1-8D61-EFDFA20160C9

Q36782688-32AEF3E4-43BE-4B34-9598-0C1D55780BE5

Q36782688-3C299AE0-AE9F-4F8B-9C11-3EEDAB30BA46

Q36782688-3D904DC0-BBCB-44DA-A533-BC2B9C35D678

Q36782688-455F23FF-DC15-4AFD-8459-E47A428A4BE4

Q36782688-4C352B80-00AE-49AD-9B94-27C2BACBA9DA

Q36782688-51AADBB1-1A01-49ED-9B99-671FD7B1D884

Q36782688-59B87C42-E3FA-4C52-83DC-ECBB63650332

Q36782688-684EB011-56E1-4C56-AE3A-6C8994F944E1

P2860

Q36782688-02910881-E861-46BD-9C00-2DC7C1683A1B

Q36782688-033B7E64-D8B9-4587-93F8-706D9B309033

Q36782688-1B005AE7-2E68-437A-8B2F-7129F916558E

Q36782688-1CBF2B9F-8483-452A-B61D-C912B8958174

Q36782688-1E3D31E8-C088-496F-8903-838BC267A653

Q36782688-225E553E-ACA0-4CFE-BB59-748074BAADDE

Q36782688-25B958E5-8F22-452E-951D-DD53D6E5BD57

Q36782688-288F59CC-A976-4DD8-88D9-F41637A5534C

Q36782688-325E5E4F-CBE3-491F-817F-40E2D6AD5996

Q36782688-421BB8D7-F621-4AC4-94E9-E310EFF9487D

P304

Q36782688-AFB20520-0B71-4D35-8B6D-FA7C60640552

P31

Q36782688-58A2FF0F-8F3B-4A23-AC95-97AAA56E9793

P356

Q36782688-CA517295-955F-4DF5-8553-F2DADACEBCD0

P407

Q36782688-C613A9CA-4DD2-4F69-8C39-713466038A1D

P433

Q36782688-3BFFD29E-223A-4038-97ED-85FA82C6BF4E

P478

Q36782688-D29975C7-A7BF-4DAB-AEDA-8A846A9DB400

P577

Q36782688-D3D5A843-5E67-47E3-B006-E6BF57EDE625

P5875

Q36782688-CA035E3C-1FB0-4932-A64E-2218058CA8C0

P698

Q36782688-20B77450-E76E-4627-B365-B213CDBB92EE

P921

Q36782688-1A0BA005-C2E7-40F3-AE10-205469376128

Q36782688-788A5C4E-3FBD-4BB2-BDEA-382AB6377BF3

Q36782688-DC8C685F-0CE5-45E3-B3AC-5945FBE486F3

P932

Q36782688-DD498B8E-C14C-40FB-A1FE-6C2E814FBDAC

P356

P1433

P1476

Effects of metformin versus gl ...... s and coronary artery disease.

@en

P2093

Ankang Lv

http://www.w3.org/2001/XMLSchema#string

Chao Liu

http://www.w3.org/2001/XMLSchema#string

Dajin Zou

http://www.w3.org/2001/XMLSchema#string

Dalong Zhu

http://www.w3.org/2001/XMLSchema#string

Dawang Wang

http://www.w3.org/2001/XMLSchema#string

Guang Ning

http://www.w3.org/2001/XMLSchema#string

Guoting Wu

http://www.w3.org/2001/XMLSchema#string

Hong Li

http://www.w3.org/2001/XMLSchema#string

Jiajun Zhao

http://www.w3.org/2001/XMLSchema#string

Jie Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin: An Update

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.

Pharmacologic therapy for type 2 diabetes mellitus.

P304

1304-1311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC12-0719

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233892644

http://www.w3.org/2001/XMLSchema#string

P698

23230096

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3631843

http://www.w3.org/2001/XMLSchema#string